Merck to Acquire Imago BioSciences, Inc. for USD 1.35 Billion
While its rumored acquisition of Seagen has yet to materialize, Merck & Co has continued to bolster its pipeline with smaller transactions, the most recent of which was a USD 1.35 billion agreement to acquire Imago BioSciences and its bomedemstat drug candidate for blood disorders. The USD 36 per share bolt-on deal contributes to Merck's R&D portfolio as it seeks to reduce the proportion of its sales from the USD 17 billion-plus immuno-oncology blockbuster Keytruda (pembrolizumab) and build a hematology franchise.
Bomedemstat (IMG-7289), an oral lysine-specific demethylase 1 (LSD1) inhibitor, ...
